drugset / Trial / NCT07312188

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

NCT07312188

Phase 2 Recruiting 90 enrolled Shandong New Time Pharmaceutical Co., LTD
NaSequentialOpen-labelTreatment

Summary

This is a single - arm, multi - cohort, open - label, multi - center Phase II clinical study. It aims to evaluate the efficacy and safety of F182112 combined with different administration regimens in patients with relapsed or refractory multiple myeloma.

Timeline

Start
2025-07-02
Primary completion
2028-05-20
Completion
2028-05-20

Drugs

EvaluationDrugModalityDoseRoute
Subject F182112 Unknown
Subject Pomalidomide Other / unclassified